XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200
Debt
Debt-to-Equity Ratio3.06
Current Ratio12.46
Quick Ratio12.46
Price-To-Earnings
Trailing P/E Ratio16.14
Forward P/E Ratio-16.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$52.69 million
Price / Sales2.52
Cash Flow$1.8247 per share
Price / Cash8.67
Book Value$0.71 per share
Price / Book22.28
Profitability
EPS (Most Recent Fiscal Year)$0.98
Net Income$14.59 million
Net Margins43.55%
Return on Equity379.39%
Return on Assets43.03%
Miscellaneous
Employees12
Outstanding Shares8,390,000
Market Cap$154.57 million
XOMA (NASDAQ:XOMA) Frequently Asked Questions
What is XOMA's stock symbol?
XOMA trades on the NASDAQ under the ticker symbol "XOMA."
How were XOMA's earnings last quarter?
XOMA Corp (NASDAQ:XOMA) released its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.03. The biotechnology company had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.57 million. XOMA had a return on equity of 379.39% and a net margin of 43.55%. View XOMA's Earnings History.
When is XOMA's next earnings date?
What price target have analysts set for XOMA?
3 brokers have issued 1 year price objectives for XOMA's stock. Their forecasts range from $16.26 to $49.00. On average, they anticipate XOMA's stock price to reach $32.7533 in the next year. This suggests a possible upside of 107.0% from the stock's current price. View Analyst Price Targets for XOMA.
What is the consensus analysts' recommendation for XOMA?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.
Who are some of XOMA's key competitors?
Some companies that are related to XOMA include AC Immune (ACIU), Progenics Pharmaceuticals (PGNX), Dova Pharmaceuticals (DOVA), Eidos Therapeutics (EIDX), Verastem (VSTM), Collegium Pharmaceutical (COLL), Prothena (PRTA), ArQule (ARQL), ChemoCentryx (CCXI), Homology Medicines (FIXX), Insys Therapeutics (INSY), Evolus (EOLS), Obseva (OBSV), TIGENIX/S (TIG) and CannTrust (CNTTF).
Who are XOMA's key executives?
XOMA's management team includes the folowing people:
- Mr. James R. Neal, CEO & Director (Age 62)
- Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)
- Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)
- Dr. Deepshikha Datta, Chief Bus. Officer
- Dr. Kirk W. Johnson Ph.D., VP of Devel. (Age 58)
Has XOMA been receiving favorable news coverage?
Media stories about XOMA stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. XOMA earned a media and rumor sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 48.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for XOMA.
Who are XOMA's major shareholders?
XOMA's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.36%), Acadian Asset Management LLC (1.15%), Macquarie Group Ltd. (0.82%), Spark Investment Management LLC (0.62%), Bank of New York Mellon Corp (0.43%) and Strs Ohio (0.39%). Company insiders that own XOMA stock include James R Neal, John Varian, Patrick J Md Phd Scannon and Thomas M Burns. View Institutional Ownership Trends for XOMA.
Which institutional investors are selling XOMA stock?
XOMA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Macquarie Group Ltd.. Company insiders that have sold XOMA company stock in the last year include James R Neal and Thomas M Burns. View Insider Buying and Selling for XOMA.
Which institutional investors are buying XOMA stock?
XOMA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Strs Ohio, Schwab Charles Investment Management Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP, Bank of New York Mellon Corp and Alps Advisors Inc.. View Insider Buying and Selling for XOMA.
How do I buy shares of XOMA?
Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XOMA's stock price today?
One share of XOMA stock can currently be purchased for approximately $15.82.
How big of a company is XOMA?
XOMA has a market capitalization of $154.57 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.
How can I contact XOMA?
XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]
MarketBeat Community Rating for XOMA (NASDAQ XOMA)
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
